TY - JOUR
T1 - Biological behavior of the intramucosal Helicobacter pylori-negative undifferentiated-type early gastric cancer
T2 - comparison with Helicobacter pylori-positive early gastric cancer
AU - Horiuchi, Yusuke
AU - Fujisaki, Junko
AU - Yamamoto, Noriko
AU - Shimizu, Tomoki
AU - Miyamoto, Yuji
AU - Tomida, Hideomi
AU - Taniguchi, Chika
AU - Morishige, Kenjiro
AU - Omae, Masami
AU - Ishiyama, Akiyoshi
AU - Yoshio, Toshiyuki
AU - Hirasawa, Toshiaki
AU - Yamamoto, Yorimasa
AU - Tsuchida, Tomohiro
AU - Igarashi, Masahiro
AU - Nakajima, Toshifusa
AU - Takahashi, Hiroshi
N1 - Publisher Copyright:
© 2014, The International Gastric Cancer Association and The Japanese Gastric Cancer Association.
PY - 2016/1/1
Y1 - 2016/1/1
N2 - Background: The differences in the growth morphology, proliferative ability, and background mucosa of the cancer between Helicobacter pylori (HP)-positive (HP+) gastric cancer (GC) and HP-negative (HP−) GC are still unclear. To clarify the differences, we compared the characteristics of the two types of cancer. Methods: Of the 91 patients with undifferentiated-type early GC who underwent endoscopic treatment at our hospital between August 2005 and April 2011, 23 HP− GC patients (all of whom had signet ring cell carcinoma measuring 20 mm or less in diameter) and 46 HP+ GC patients with signet ring cell carcinoma measuring 20 mm or less in diameter (out of a total of 68 HP+ GC patients) were enrolled in this study. Endoscopic atrophy and background mucosa were classified according to the updated Sydney system. The proliferative capacity of the cancer was assessed by examining the MIB-1 labeling index. Results: With regard to the growth in the mucosal layer, the proportion of patients with cancer confined to the proliferative zone was significantly higher in the HP− GC group. Moderate or severer atrophy, intestinal metaplasia, mononuclear cell infiltration, and neutrophil infiltration according to the updated Sydney system were significantly commoner in the HP+ GC patients. Also, the MIB-1 labeling index was significantly higher in the HP+ GC group. Conclusion: HP+ GC appeared to show a higher proliferative capacity, more extensive spread, and more rapid progression, and inflammation associated with HP infection was suggested to be involved in the proliferation of this type of GC.
AB - Background: The differences in the growth morphology, proliferative ability, and background mucosa of the cancer between Helicobacter pylori (HP)-positive (HP+) gastric cancer (GC) and HP-negative (HP−) GC are still unclear. To clarify the differences, we compared the characteristics of the two types of cancer. Methods: Of the 91 patients with undifferentiated-type early GC who underwent endoscopic treatment at our hospital between August 2005 and April 2011, 23 HP− GC patients (all of whom had signet ring cell carcinoma measuring 20 mm or less in diameter) and 46 HP+ GC patients with signet ring cell carcinoma measuring 20 mm or less in diameter (out of a total of 68 HP+ GC patients) were enrolled in this study. Endoscopic atrophy and background mucosa were classified according to the updated Sydney system. The proliferative capacity of the cancer was assessed by examining the MIB-1 labeling index. Results: With regard to the growth in the mucosal layer, the proportion of patients with cancer confined to the proliferative zone was significantly higher in the HP− GC group. Moderate or severer atrophy, intestinal metaplasia, mononuclear cell infiltration, and neutrophil infiltration according to the updated Sydney system were significantly commoner in the HP+ GC patients. Also, the MIB-1 labeling index was significantly higher in the HP+ GC group. Conclusion: HP+ GC appeared to show a higher proliferative capacity, more extensive spread, and more rapid progression, and inflammation associated with HP infection was suggested to be involved in the proliferation of this type of GC.
KW - Endoscopic gastrointestinal surgery
KW - Gastric cancer
KW - Helicobacter pylori
KW - Undifferentiated-type carcinoma
UR - https://www.scopus.com/pages/publications/84951567878
UR - https://www.scopus.com/pages/publications/84951567878#tab=citedBy
U2 - 10.1007/s10120-014-0452-1
DO - 10.1007/s10120-014-0452-1
M3 - Article
C2 - 25491775
AN - SCOPUS:84951567878
SN - 1436-3291
VL - 19
SP - 160
EP - 165
JO - Gastric Cancer
JF - Gastric Cancer
IS - 1
ER -